(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Instructions to Comprehend and Use Open Record Extra Offers - 2Surprise! Saturn's huge moon Titan may not have a buried ocean after all
- 3German hauliers warn soaring energy prices may soon impact consumers
- 4Huge solar flare no threat to Artemis 2 astronaut launch to the moon, NASA says
- 5Foot fossil discovery could reshape human evolutionary history
- Public Parks in the USA
- The most effective method to Shake Hands During a Pandemic: Wellbeing Tips and Behavior
- Why the weirdest sea level changes on Earth are happening off the coast of Japan
- The Force of Organic product: 10 Assortments That Improve Your Wellbeing
- China Just Got Another Cheap EV America Would Love to Have
- Great DSLR Cameras for Photography Devotees
- Israel strikes Iranian nuclear development facilities, Tehran vows retaliation
- Fundamental Home Exercise center Hardware: Amplify Your Exercises
- Dinosaur collagen used to create one-of-a-kind handbag
